Intangible Assets, Net (Narrative) (Details) (USD $) In Thousands, unless otherwise specified	1 Months Ended	0 Months Ended	1 Months Ended				3 Months Ended	6 Months Ended
	Jun. 30, 2011	Apr. 24, 2011	Jul. 31, 2010	May 31, 2010	Apr. 30, 2010	Mar. 31, 2009 years	Jun. 30, 2011	Jun. 30, 2011	Jun. 30, 2010
Amortization expense related to intangible assets								$ 6,118	$ 8,154
Intangible asset impairment charges							27,660
Payments to MonoSol Rx approval milestone			4,000
Workforce eliminated	90
Payments to MonoSol Rx pre-launch milestone			2,000
Number of days of marketing exclusivity				180
Payment to Glenmark for exclusive rights to market, sell and distribute the product in the U.S.		15,000
Payments made under license agreements					20,000
Payments made to acquire Nascobal Nasal Spray rights						54,500
Amortization period for Nascobal Nasal Spray rights						12
Intangible Asset Impairments [Member]
Intangible asset impairment charges							$ 24,226	$ 24,226